Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes’ C colon cancer. - Twelves,C.; Wong,A.; Nowacki,M. (Proc Am Soc Clin Oncol, 2005)